SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Cancer

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2015.06.122PMID 26169017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trans‐Pacific variation in outcomes for men treated with primary androgen‐deprivation therapy (ADT) for prostate cancer

  2016cited by this paper
• Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.

  2015influential reference
• Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

  2015cited by this paper
• The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy

  2015cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• 5α‐reductase type 3 enzyme in benign and malignant prostate

  2014cited by this paper
• Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

  2014influential reference
• Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

  2014cited by this paper
• Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation

  2013cited by this paper
• Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer

  2013influential reference
• Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity

  2013cited by this paper
• Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.

  2013cited by this paper
• Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

  2012influential reference
• SRD5A polymorphisms and biochemical failure after radical prostatectomy.

  2011influential reference
• Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

  2011influential reference
• Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.

  2011cited by this paper
• Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.

  2011cited by this paper
• Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.

  2011cited by this paper
• Targeting 5α-reductase for prostate cancer prevention and treatment

  2011cited by this paper
• An update on androgen deprivation therapy for prostate cancer.

  2010cited by this paper
• Effect of dutasteride on the risk of prostate cancer.

  2010influential reference
• Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.

  2009influential reference
• Combined androgen blockade with bicalutamide for advanced prostate cancer

  2009cited by this paper
• Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.

  2009influential reference
• Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

  2008influential reference
• V89L Polymorphism of the 5α-Reductase Type II Gene (SRD5A2), Endogenous Sex Hormones, and Prostate Cancer Risk

  2008influential reference
• Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.

  2008cited by this paper
• Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

  2008influential reference
• Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

  2007influential reference
• 5α‐Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia

  2007influential reference
• Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.

  2007cited by this paper
• Novel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancer

  2007cited by this paper
• Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men

  2006influential reference
• Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

  2006influential reference
• Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers

  2006influential reference
• Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer

  2005influential reference
• Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.

  2005cited by this paper
• The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.

  2005cited by this paper
• Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk

  2004cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003influential reference
• Polymorphisms in the androgen receptor and type II 5α‐reductase genes and prostate cancer prognosis

  2002cited by this paper
• Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II.

  2000cited by this paper
• A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.

  1997cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper

• SRD5A2 and emerging therapies in androgen-driven disorders.

  2026cites this paper
• Restraining SRD5A1 combined with BRD4 inhibitor delaying prostate cancer progression by decreasing AR expression.

  2025cites this paper
• Sex hormone-binding globulin and its critical role in prostate cancer: A comprehensive review.

  2024cites this paper
• Genome-wide association study of blood lipid levels in Southern Han Chinese adults with prediabetes

  2024cites this paper
• Enhancing Metabolome Annotation by Electron Impact Excitation of Ions from Organics-Molecular Networking.

  2024cites this paper
• Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer

  2023cites this paper
• Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer

  2023cites this paper
• A Phase II Trial of Abiraterone With Dutasteride for Second‐Generation Antiandrogen‐ and Chemotherapy‐Naïve Patients With Castration‐Resistant Prostate Cancer

  2022cites this paper
• Risk Allele Frequency Analysis and Risk Prediction of Single-Nucleotide Polymorphisms for Prostate Cancer

  2022cites this paper
• Prostate Cancer Mortality Associated with Aggregate Polymorphisms in Androgen-Regulating Genes: The Atherosclerosis Risk in the Communities (ARIC) Study

  2021influential citation
• In vitro and in vivo investigation of the therapeutic mechanism of Lycium Chinense and Cuscutae Semen on oligoasthenozoospermia

  2021cites this paper
• Epidemiology and genomics of prostate cancer in Asian men

  2021cites this paper
• The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer

  2021cites this paper
• Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer

  2021cites this paper
• Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.

  2021cites this paper
• Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer

  2021cites this paper
• Metabolic regulation of prostate cancer heterogeneity and plasticity.

  2020cites this paper
• Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

  2020cites this paper
• Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.

  2020cites this paper
• Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer

  2020cites this paper
• Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men

  2020cites this paper
• Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone

  2019cites this paper
• The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men

  2019cites this paper
• A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy

  2019cites this paper
• Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer

  2019cites this paper
• Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men.

  2019cites this paper
• Genetic markers a landscape in prostate cancer.

  2018cites this paper
• Genetic Polymorphism Analysis in Predicting Prognosis of Advanced Prostate Cancer

  2018cites this paper
• Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer

  2018cites this paper
• Sex steroids in the tumor microenvironment and prostate cancer progression.

  2018cites this paper
• The Association of Polymorphisms in the Gene Encoding Gonadotropin‐Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer

  2017cites this paper
• A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer

  2017cites this paper
• The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism

  2016cites this paper
• The Role of Nuclear Factor Kappa B in Benign Prostatic Hyperplasia

  2016cites this paper
• Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.

  2016cites this paper
• Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress

  2016cites this paper